Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 20.57% | 329.63 | 0.0% | $4354.99m | |
| BNTX | BioNTech SE | 14.19% | 348.00 | 0.0% | $1400.74m | |
| NVAX | Novavax, Inc. | 8.95% | 217.97 | 78.2% | $1098.56m | |
| AMGN | Amgen, Inc. | -1.41% | 201.09 | 1.4% | $565.85m | |
| LGVN | Longeveron Inc. | -27.49% | 30.67 | 0.0% | $559.00m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.75% | 643.35 | 2.7% | $495.48m | |
| GILD | Gilead Sciences, Inc. | 0.29% | 70.27 | 1.0% | $491.04m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -8.16% | 4.84 | 0.7% | $338.33m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.42% | 183.59 | 1.9% | $332.99m | |
| OCGN | Ocugen, Inc. | -9.16% | 6.45 | 0.0% | $317.79m | |
| ILMN | Illumina, Inc. | 1.16% | 369.79 | 3.3% | $291.39m | |
| BIIB | Biogen, Inc. | -2.89% | 242.90 | 1.8% | $257.70m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -2.22% | 87.58 | 4.2% | $157.02m | |
| EXAS | EXACT Sciences Corp. | -2.99% | 85.46 | 18.0% | $156.18m | |
| INCY | Incyte Corp. | 2.46% | 68.38 | 2.4% | $147.61m |
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.